Celldex Therap
CLDX37.5105.42% ( +1.930 )
Celldex Therap (CLDX)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmun...
- Open
- 35.580
- High
- 37.760
- Low
- 35.580
- Prev. Close
- 35.580
- Volume
- 1.57M
- Turnover
- 58.00M
- Avg Price
- 36.882
- Bid/Ask Ratio
- --
- Amplitude
- 6.13%
- 52wk High
- 40.300
- Volume Ratio
- 1.34
- Turnover Ratio
- 2.22%
Celldex Therap Analyst Rating
View MoreForecast & Rating
Jul 29, 2026Price forecast
$57.0752.14%
Forecast & RatingStrong buy
16analysts
- Strong buy81.25%
- Buy12.50%
- Hold6.25%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 18 hours ago
Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price
- Simplywall · Jul 22 at 04:12 PM
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run
- Market Beat · Jul 22 at 02:18 PM
Wells Fargo & Company Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price
- Market Beat · Jul 22 at 08:12 AM
Cantor Fitzgerald Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price
- benzinga_article · Jul 22 at 06:29 AM
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
- PUBT · Jul 21 at 03:01 PM
Celldex ends Phase 2 barzolvolimab trial in prurigo nodularis after missing endpoint
